Outlook Therapeutics Inc

-0.06 (-2.74%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)369.78M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.3 Million
Adjusted EPS-$0.06
See more estimates
10-Day MA$2.14
50-Day MA$2.31
200-Day MA$2.24
See more pivots

Outlook Therapeutics Inc Stock, NASDAQ:OTLK

485 Route 1 South, Building F, Suite 320, Iselin, New Jersey 08830
United States of America
Phone: +1.609.619.3990
Number of Employees: 8


Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.